Home › Funds › Trails Edge Capital Partners, LP › IKT

Trails Edge Capital Partners, LP position in IKT

INHIBIKASE THERAPEUTICS INC · Health Care

Trails Edge Capital Partners, LP reported holding 9,051,318 shares of IKT (INHIBIKASE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$18.4M, representing 2.92% of its reported portfolio and ranking #16 among its reported holdings. Trails Edge Capital Partners, LP has disclosed IKT holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)9.05M sh
Reported value held$18.37M
Portfolio Weight2.92%
First reportedQ4 2025
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Trails Edge Capital Partners, LP's IKT position evolved

Trails Edge Capital Partners, LP first disclosed a stake in IKT in Q4 2025 at 6,178,124 shares (US$12.7M). The position peaked in Q2 2026 at 9,051,318 shares, worth US$18.4M. Across 3 filings, Trails Edge Capital Partners, LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 9,051,318 shares valued at US$18.4M — an increase of 993,973 shares quarter over quarter.. Notable position changes include a 30% increase in Q1 2026 (shares rose 21% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 6.18M $12.67M New
Q1 2026 8.06M $13.54M Add
Q2 2026 9.05M $18.37M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About IKT and 13F data

IKT (INHIBIKASE THERAPEUTICS INC) is a Health Care company. 69 other funds we track also report a position in IKT — the largest reported positions include Sands Capital Alternatives, LLC (US$26.4M), Soleus Capital Management, L.P. (US$22.1M), Fairmount Funds Management LLC (US$17.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding IKT

All IKT fund holders →

FAQ

How long has Trails Edge Capital Partners, LP held IKT?

Trails Edge Capital Partners, LP has disclosed IKT holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is Trails Edge Capital Partners, LP's current position in IKT?

As of Q2 2026, Trails Edge Capital Partners, LP holds 9.05M shares of IKT (INHIBIKASE THERAPEUTICS INC), valued at $18.37M, representing 2.92% of its reported portfolio and ranking #16.

Has Trails Edge Capital Partners, LP been buying or selling IKT?

In the latest 13F filing (Q2 2026), Trails Edge Capital Partners, LP increased its position in IKT. The position peaked in Q2 2026 at 9.05M shares.

Which other funds hold IKT?

Other major institutional holders of IKT include Sands Capital Alternatives, LLC, Soleus Capital Management, L.P., Fairmount Funds Management LLC, among 69 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.